Navigation Links
Radioimmunotherapy After Chemo Safe for Common Lymphoma
Date:3/13/2008

Combo treatment improved overall survival rates in follicular non-Hodgkin lymphoma

THURSDAY, March 13 (HealthDay News) -- Radioimmunotherapy after chemotherapy is safe and effective for patients with follicular non-Hodgkin lymphoma (NHL), according to an Italian study.

It found that radioimmunotherapy with the radioactive drug yttrium-90 (90Y) ibritumombab tiuxetan, following chemotherapy with fludarabine and mitoxantrone is feasible, well-tolerated and effective in follicular NHL patients.

The study began with 61 patients who received six cycles of oral fludarabine and intravenous mitoxantrone. Of these, 57 (43 with complete response and 14 with partial response) were deemed eligible for subsequent radioimmunotherapy with 90Y- ibritumombab tiuxetan. After that treatment, 12 of the 14 partial response patients achieved complete response.

At a median follow-up of 30 months, three-year progression-free survival among the 57 patients was 76 percent, and three-year overall survival was 100 percent. Grade 3 or 4 hematological effects were noted in 36 of the 57 patients.

"This study has established the feasibility, tolerability, and efficacy of sequential treatment with six cycles of fludarabine and mitoxantrone chemotherapy followed by 90Y- ibritumombab tiuxetan as a front-line treatment for untreated patients with follicular NHL. In particular, the data represent the first evidence of a role of 90Y- ibritumombab tiuxetan after a fludarabine-containing regimen in the treatment of follicular NHL," the study authors concluded.

The findings were published online this week in The Lancet Oncology, and were expected to be published in the April print edition of the journal.

Follicular NHL -- the most common form of lymphoma in Europe and the United States -- accounts for about 30 percent of all newly diagnosed NHLs.

More information

The Lymphoma Research Foundation outlines common forms of lymphoma.



-- Robert Preidt



SOURCE: The Lancet, news release, March 12, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Work-Family Conflict Dogs Air Force Women After Deployment
2. Work-Family Conflict Dogs Air Force Women After Deployment
3. Stopping Statins After Stroke Doubles Death Risk
4. Billy Graham Home After Hospitalization:
5. Swelling After Knee Injury May Hinder Healing
6. Going on After Loss
7. Discover The Mutter Museum After Dark
8. Cialis Eases Erectile Dysfunction After Spinal Cord Injury
9. Perrigo Vice Chair Mori Arkin To Retire After 30 Years of Service
10. Vitamin Relief Brings Needed Nutrition to School District Resurrecting After Katrina
11. Pill Equals Injection in Preventing Clots After Hip Replacement
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Radioimmunotherapy After Chemo Safe for Common Lymphoma
(Date:1/17/2017)... Michigan (PRWEB) , ... January 17, 2017 , ... January is National Stalking Awareness ... who choose to lurk in the corners and commit the crime of stalking, a very ... use and addiction, an often overlooked factor in stalking and other crimes. , “Stalking: know ...
(Date:1/17/2017)... ... January 17, 2017 , ... Anesthesia Progress – Everyone wants less ... best drug option for each patient. Dentists have several general anesthesia alternatives and finding ... Researchers from the Tokyo Dental College in Tokyo, Japan wanted to find out which ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Gym Source, ... of a new showroom at South Dixie Hwy in Miami, FL. , “We are ... Gym Source. “The new innovative in-store concept is designed to give clients a seamless ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... point of difference. Eden Activewear is a stand-out company for several differences from ... online and only manufacture on demand, this is called 'Agile' manufacturing - ...
(Date:1/17/2017)... ... January 17, 2017 , ... For breast cancer clinicians and researchers who were ... desire a more intimate review and analysis of its highlights, a novel half-day, complimentary ... offered by Imedex on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... ® Technologies, Inc. announces that the Journal ... of Vibration on Molar Distalization," a study that focused ... Bowman , this prospective, peer-reviewed clinical study concluded that ... speeds up molar distalization rates in the apex ... to move the upper molars into a normal, Class ...
(Date:1/17/2017)... , Jan. 17, 2017 Following an ... today praised the Food and Drug Administration,s (FDA,s) ... Human Drug Products by Pharmacies and Outsourcing Facilities." ... proposed limitation on pre-packaging -- which would have ... costs to long term care (LTC) pharmacies.  ...
(Date:1/17/2017)... 2017 Research and Markets has announced the ... Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone) Drug ... 2021" report to their offering. ... The global active pharmaceutical ingredients market is ... Billion in 2016, growing at a CAGR of 6.3% from 2016 ...
Breaking Medicine Technology: